Enrichment.KEGG_urine day 24 female Hgf-Cdk4R24C;;;;;; #term ID;term description;observed gene count;background gene count;false discovery rate;matching proteins in your network (IDs);matching proteins in your network (labels) mmu04060;Cytokine-cytokine receptor interaction;9;252;6.45e-12;ENSMUSP00000000193,ENSMUSP00000001008,ENSMUSP00000019060,ENSMUSP00000027061,ENSMUSP00000028881,ENSMUSP00000028882,ENSMUSP00000031327,ENSMUSP00000046960,ENSMUSP00000078705;Ccl2,Ccl3,Csf2,Cxcl1,Il17a,Il17f,Il1a,Il1b,Tnfrsf11b mmu05323;Rheumatoid arthritis;6;81;1.38e-09;ENSMUSP00000000193,ENSMUSP00000001008,ENSMUSP00000019060,ENSMUSP00000027061,ENSMUSP00000028881,ENSMUSP00000028882;Ccl2,Ccl3,Csf2,Il17a,Il1a,Il1b mmu04657;IL-17 signaling pathway;6;91;1.79e-09;ENSMUSP00000000193,ENSMUSP00000019060,ENSMUSP00000027061,ENSMUSP00000028881,ENSMUSP00000031327,ENSMUSP00000046960;Ccl2,Csf2,Cxcl1,Il17a,Il17f,Il1b mmu05132;Salmonella infection;5;78;7.26e-08;ENSMUSP00000001008,ENSMUSP00000019060,ENSMUSP00000028881,ENSMUSP00000028882,ENSMUSP00000031327;Ccl3,Csf2,Cxcl1,Il1a,Il1b mmu04668;TNF signaling pathway;5;108;2.77e-07;ENSMUSP00000000193,ENSMUSP00000019060,ENSMUSP00000020949,ENSMUSP00000028881,ENSMUSP00000031327;Ccl2,Csf2,Cxcl1,Il1b,Map2k6 mmu05321;Inflammatory bowel disease (IBD);4;58;1.59e-06;ENSMUSP00000027061,ENSMUSP00000028881,ENSMUSP00000028882,ENSMUSP00000046960;Il17a,Il17f,Il1a,Il1b mmu04380;Osteoclast differentiation;4;122;2.38e-05;ENSMUSP00000020949,ENSMUSP00000028881,ENSMUSP00000028882,ENSMUSP00000078705;Il1a,Il1b,Map2k6,Tnfrsf11b mmu05418;Fluid shear stress and atherosclerosis;4;140;3.54e-05;ENSMUSP00000000193,ENSMUSP00000020949,ENSMUSP00000028881,ENSMUSP00000028882;Ccl2,Il1a,Il1b,Map2k6 mmu05164;Influenza A;4;165;5.93e-05;ENSMUSP00000000193,ENSMUSP00000020949,ENSMUSP00000028881,ENSMUSP00000028882;Ccl2,Il1a,Il1b,Map2k6 mmu04640;Hematopoietic cell lineage;3;90;0.00034;ENSMUSP00000019060,ENSMUSP00000028881,ENSMUSP00000028882;Csf2,Il1a,Il1b mmu04010;MAPK signaling pathway;4;292;0.00040;ENSMUSP00000020949,ENSMUSP00000028881,ENSMUSP00000028882,ENSMUSP00000032066;Il1a,Il1b,Map2k6,Tgfa mmu04620;Toll-like receptor signaling pathway;3;98;0.00040;ENSMUSP00000001008,ENSMUSP00000020949,ENSMUSP00000028881;Ccl3,Il1b,Map2k6 mmu04659;Th17 cell differentiation;3;100;0.00040;ENSMUSP00000027061,ENSMUSP00000028881,ENSMUSP00000046960;Il17a,Il17f,Il1b mmu04933;AGE-RAGE signaling pathway in diabetic complications;3;100;0.00040;ENSMUSP00000000193,ENSMUSP00000028881,ENSMUSP00000028882;Ccl2,Il1a,Il1b mmu05142;Chagas disease (American trypanosomiasis);3;101;0.00040;ENSMUSP00000000193,ENSMUSP00000001008,ENSMUSP00000028881;Ccl2,Ccl3,Il1b mmu04217;Necroptosis;3;158;0.0011;ENSMUSP00000027777,ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b,Parp1 mmu04621;NOD-like receptor signaling pathway;3;164;0.0012;ENSMUSP00000000193,ENSMUSP00000028881,ENSMUSP00000031327;Ccl2,Cxcl1,Il1b mmu04062;Chemokine signaling pathway;3;179;0.0014;ENSMUSP00000000193,ENSMUSP00000001008,ENSMUSP00000031327;Ccl2,Ccl3,Cxcl1 mmu05020;Prion diseases;2;34;0.0014;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu05167;Kaposi's sarcoma-associated herpesvirus infection;3;203;0.0018;ENSMUSP00000019060,ENSMUSP00000020949,ENSMUSP00000031327;Csf2,Cxcl1,Map2k6 mmu05144;Malaria;2;45;0.0021;ENSMUSP00000000193,ENSMUSP00000028881;Ccl2,Il1b mmu05332;Graft-versus-host disease;2;54;0.0028;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu04940;Type I diabetes mellitus;2;59;0.0030;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu05134;Legionellosis;2;57;0.0030;ENSMUSP00000028881,ENSMUSP00000031327;Cxcl1,Il1b mmu04664;Fc epsilon RI signaling pathway;2;66;0.0035;ENSMUSP00000019060,ENSMUSP00000020949;Csf2,Map2k6 mmu05140;Leishmaniasis;2;65;0.0035;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu05133;Pertussis;2;74;0.0042;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu04064;NF-kappa B signaling pathway;2;93;0.0062;ENSMUSP00000027777,ENSMUSP00000028881;Il1b,Parp1 mmu05146;Amoebiasis;2;105;0.0076;ENSMUSP00000019060,ENSMUSP00000028881;Csf2,Il1b mmu04750;Inflammatory mediator regulation of TRP channels;2;119;0.0094;ENSMUSP00000020949,ENSMUSP00000028881;Il1b,Map2k6 mmu05162;Measles;2;132;0.0110;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu04932;Non-alcoholic fatty liver disease (NAFLD);2;146;0.0130;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu04218;Cellular senescence;2;171;0.0170;ENSMUSP00000020949,ENSMUSP00000028882;Il1a,Map2k6 mmu05152;Tuberculosis;2;172;0.0170;ENSMUSP00000028881,ENSMUSP00000028882;Il1a,Il1b mmu05168;Herpes simplex infection;2;202;0.0220;ENSMUSP00000000193,ENSMUSP00000028881;Ccl2,Il1b